Prulifloxacin


Generic Medicine Info
Contraindications
Hypersensitivity. Pregnancy and lactation. Children or adolescents below 18 yr with uncomplicated skeletal development. History of tendon diseases related to administration of quinolones. Celiac disease.
Special Precautions
Haemolytic reactions may occur in G6PD deficiency patients. Exposure to sun or UV-ray may cause photosensitivity reactions. Lowers seizure threshold and predisposes CNS disorder patients to convulsions. Caution in patients with hypokalaemia, hypocalcaemia, or in patients who suffer from rhythm disorders. Increased risk of Achilles tendon or other tendon damage especially in elderly patients, concurrent corticosteroids-receiving patients or organ transplant recipients. Crystalluria, rhadomyolysis may occur in rare cases. Prolonged use may result in development of drug-resistant bacteria, or superinfections including Clostridium difficile-associated diarrhoea and pseudomembranous colitis. Renal impairment.
Adverse Reactions
Nausea, vomiting, epigastric pain, gastritis, diarrhoea, fever, altered taste, cephalalgia, dizziness, drowsiness, sleep disorders, ocular hyperemia, pruritis, skin rash, facial eczema, photosensitivity, muscle spasm, rhabdomyolysis, anorexia.
Potentially Fatal: Hypersensitivity, anaphylactic/anaphylactoid reactions, Stevens-Johnson syndrome.
Drug Interactions
Concurrent use with cimetidine, aluminium- and magnesium-containing antacids, or preparations containing iron and calcium reduces the absorption of Prulifloxacin. Increased concentration with probenecid. Prulifloxacin may increase serum concentration of theophylline. Quinolones may enhance hypoglycaemic effect of hypoglycaemic agents. May enhance effect of oral anticoagulants such as warfarin and its derivatives. Concurrent use of NSAIDS may increase risk of convulsions.
CIMS Class
Quinolones
ATC Classification
J01MA17 - prulifloxacin ; Belongs to the class of fluoroquinolones. Used in the systemic treatment of infections.
Disclaimer: This information is independently developed by CIMS based on prulifloxacin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in